SavedAdd your journal

Journals / Solunum Hastalıkları / 2002 / Cilt: 13 - Sayı: 2

Evaluation of the efficacy and tolerance of cisplatin / vinorelbine combination in nonsmall cell lung cancer

İnoperabl küçük hücreli dışı akciğer kanserlerinde sisplatin / vinorelbin kemoterapisinin etkinliği

Can ÖZTÜRK
Nurdan KÖKTÜRK
Melike ŞENER
ENDER LEVENT
Gül GÜRSEL
Pages
101–105
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The median overall survival was 12 months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The purpose of this study is to evaluate efficacy, toxicity of the combination chemotherapy regimen with cisplatin/vinorelbine (CDDP/VNR).
📊
Key Findings & Data:Thirty one consecutive patients (27 men, 4 women) were enrolled. 20 patients were stage 4, 11 were stage 3B.
💡
Conclusion & Impact:The median overall survival was 12 months.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Antineoplastik birleşik kemoterapi protokolleri · Sisplatin · İlaç toksisitesi

Abstract

The purpose of this study is to evaluate efficacy, toxicity of the combination chemotherapy regimen with cisplatin/vinorelbine (CDDP/VNR). Thirty one consecutive patients (27 men, 4 women) were enrolled. 20 patients were stage 4, 11 were stage 3B. Patients were treated with CDDP 80 mg/m2 on day 1 and VNR 25 mg/m2 on day 1 and 8. The cycle was repeated every 21 days. One hundred five courses were completed. Grade 2 and more hematologic toxicity occured in 30/105 courses. Objective response rate was 58% with complete remission in 3.2% and partial response in 54% patients. Three patients (9.7%) had stable diseases and 10 patients (32%) had progression. The median response duration was 6 months (2-9 months) in the evaluated 13 patients. The median overall survival was 12 months. These findings suggest that the combination of CDDP and VNR appears to be suitable for the first line treatment of locally advanced and metastatic NSCLC.

Özet

Bu çalışmada amaç, ileri evre küçük hücreli dışı akciğer kanserlerinde (KHDAK); sisplatin/vinorelbin (CDDP/VNR) kombine kemoterapi rejiminin etkinliğini, güvenilirliğini ve toksisitesini değerlendirmektir. Çalışmaya 4'ü kadın, 27'si erkek, toplam 31 hasta alınmıştır. Hastaların 20'si evre 4, 11 'i evre 3B'dir. Hastalara 80 mg/m2 CDDP 1. gün ve 25 mg/m2 VNR 1. ve 8. günler olmak üzere 21 günlük sikluslar halinde toplam 6 kür kemoterapi (KT) verilmiştir. Otuzbir hastanın 1 (%3.2)'inde tam remisyon, 17 (%54.8)'sinde parsiyel yanıt, 3 (%9.7)'ünde stabil hastalık, 10 (%32)'unda progresyon gelişirken, median remisyon süresi, yanıtları değerlendirilebilen 13 hastada 6 ay (2-9 ay) olarak saptanmıştır. Median sağkalım süresi 12 aydır. Uygulanan 105 siklusun 30 (%29)'unda grade 2 (WHO) ve üzeri hematolojik toksisite, 2 (%2)'sinde grade 2 nefrotoksisite; 31 hastanın 9 (%29)'unda cilt toksisitesi gelişmiştir. Sonuç olarak, elde edilen yüksek yanıt oranı, düşük toksisite ve oldukça iyi tolere edilmesi nedeniyle CDDP/VNR kombinasyonu ileri evre KHDAK'lar için ilk basamak tedavi seçeneği olarak uygun bulunmuştur.

🔖

Cite This Article

ÖZTÜRK, C., KÖKTÜRK, N., ŞENER, M., LEVENT, E., GÜRSEL, G. (2002). Evaluation of the efficacy and tolerance of cisplatin / vinorelbine combination in nonsmall cell lung cancer. Solunum Hastalıkları, Cilt: 13 - Sayı: 2, 101–105. https://ajindex.com/articles/318648

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Le Chevalier T, Brisgard D, Douillard JY et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced nonsmall cell lung cancer: Results of a European Multicenter Trial Including 612 Patients. J Clin Oncol 1994;12:360-7
  2. Baldini E, Tibaldi C, Angeletti CA et al. Combination chemotherapy with vinorelbine, ifosfamide, and cispla- tin: A phase 2 study in stage 3B-4 nonsmall cell lung cancer. Sem Oncol 1994;21(Suppl 4):12-5
  3. Vokes EE, Drinkard LC, Samuels BL et al. A phase 2 study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (navelbine) for advanced nonsmall cell lung cancer: Rationale and study design. Sem Oncol 1994;21(Suppl 10):79-84
  4. NSCLC Collaborative Group. Chemotherapy in NSCLC: A meta-analysis using updated data on individual pati- ents from 52 randomized clinical trials. Br BMJ J 1995; 311:899-909
  5. Le Chevalier T, Pujol JL, Douillard JY et al. A three arm tri- al of vinorelbine (navelbine) plus cisplatin, vindesine plus cisplatin, and single agent vinorelbine in the treat- ment of nonsmall cell lung cancer: An expanded analy- sis. Sem Oncol 1994;21:28-31
  6. Coltman CA. Vinorelbine (navelbine)-a new agent for the treatment of nonsmall cell lung cancer: AQ sum- mary. Sem Oncol 1994;21(Suppl 10):1-3
  7. Schiller J, Harrigton D, Sandier A et al. A randomized pha- se III trial of four chemotherapy regimens in advanced nonsmall cell lung cancer. ASCO 2000;19:Abstract 2
  8. Kelly K, Crowley T, Bunn PA Jr et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced NSCLC: A southwest oncology group trial. ] Clin Oncol 2001;19:3210-8
  9. Coukell A), Noble S, Faulds D. Vinorelbine in advanced nonsmall cell lung cancer a pharmacoeconomic review. Pharmacoeconomics 1999;15:405-17
  10. Rapp E, Pater JL, William A et al. Chemotherapy can pro- long survival in patients with advanced nonsmall cell lung cancer- report of Canadian multicenter randomi- zed trial. ] Clin Oncol 1988;6:633-41
  11. Depierre A, Chastang Cl, Quoix E. Vinorelbine versus vi- norelbine plus cisplatin in advanced nonsmall cell lung cancer: A randomized trial. Ann Oncol 1994;5:37-42
  12. Crawford J. Update: Vinorelbine (navelbine) in nonsmall cell lung cancer. Sem Oncol 1996;23(Suppl 5):2-7
  13. Furuse K, Fukuoka M, Küba M et al. Randomized study of vinorelbine (VNR) versus vindesine (VDS) in previ- ously untreated st